Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $114.2 million.

  • Syndax Pharmaceuticals' Total Current Liabilities rose 9230.85% to $114.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.2 million, marking a year-over-year increase of 9230.85%. This contributed to the annual value of $103.5 million for FY2024, which is 7823.77% up from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Total Current Liabilities stood at $114.2 million for Q3 2025, which was up 9230.85% from $113.0 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Total Current Liabilities peaked at $114.2 million during Q3 2025, and registered a low of $20.7 million during Q4 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' median Total Current Liabilities value was $30.9 million (recorded in 2022), while the average stood at $49.4 million.
  • In the last 5 years, Syndax Pharmaceuticals' Total Current Liabilities crashed by 2754.6% in 2022 and then soared by 16602.7% in 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Total Current Liabilities (Quarter) stood at $20.7 million in 2021, then soared by 40.53% to $29.1 million in 2022, then surged by 99.88% to $58.1 million in 2023, then surged by 78.24% to $103.5 million in 2024, then increased by 10.27% to $114.2 million in 2025.
  • Its Total Current Liabilities stands at $114.2 million for Q3 2025, versus $113.0 million for Q2 2025 and $94.6 million for Q1 2025.